Collaboration to develop novel ocular therapies using CRISPR/Cas9 technology
London, 14 October 2021, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, on its strategic collaboration with Intellia Therapeutics. Intellia is a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. The collaboration will see the two companies develop novel genomic medicines using CRISPR/Cas9 technology for the treatment of ocular diseases.
The partnership is highly complementary to SparingVision’s mature and growing pipeline of unique mutation-agnostic gene therapies and combines SparingVision’s significant ophthalmology expertise with Intellia’s proprietary genome editing technology platform. Under the terms of the agreement, Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9-based genome editing technology for up to three ocular targets addressing diseases with significant unmet medical need. SparingVision will lead and fund the preclinical and clinical development for these genome-editing product candidates.
The team advising SparingVision at Consilium was Amber Fennell, Genevieve Wilson, Davide Salvi, Priit Piip and Isobel McLeod. Beyond this announcement, Consilium has provided ongoing strategic financial and corporate communications support to SparingVision, notably advising the company on its acquisition of GAMUT Therapeutics in April 2021 and its €44.5 million fundraise in October 2020.
“This collaboration marks a significant step for SparingVision as it aims to bring the most cutting edge of modern science to patients who are losing their sight and have no other options. With Intellia’s cutting-edge technology, SparingVision can further enhance its pipeline, becoming a key player in ocular genomic medicines. We are very proud to be working with the SparingVision team to communicate their story globally.”
Amber Fennell
Partner and Co-Founder of Consilium Strategic Communications
“We want to extend a huge thank you to the Consilium team for their strategic advice and guidance through the communication of this collaboration. SparingVision is now well on its way to leading a step shift in the treatment of ocular diseases and we look forward to continuing working with Consilium as we move to this exciting next stage of development.”
Stéphane Boissel
Chief Executive Officer of SparingVision
